Boehringer Ingelheim

This study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and how the body processes it, and to get early signs of whether it …

This study tests an experimental drug called BI 3034701 to help people with obesity or overweight lose weight. About 300 adults aged 18-74 will receive either the drug or a placebo injection for 42 weeks, along with diet and exercise advice. Researchers will measure weight change…

This study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows di…

This Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This study looks at how well the drug Jardiance works compared to other standard heart failure treatments in Chinese patients with a specific type of heart failure (HFrEF). Researchers will track about 5,000 adults to see which treatment better prevents heart failure hospitalizat…

This early-stage trial investigates the safety and tolerability of a new drug called BI 3031185 in healthy Japanese men, given as single or multiple doses. It also examines whether multiple doses of BI 3031185 affect how the body processes a common oral contraceptive (YAZ®) in he…

This early-stage trial will test whether taking bosentan (a drug for blood pressure) changes how the body processes zongertinib (an experimental cancer drug). Sixteen healthy men will receive zongertinib alone and then with bosentan to compare drug levels. The study is not intend…

This study will observe 3,000 adults in China with a type of heart failure called HFpEF who are starting the drug Jardiance. Researchers will track how many patients are hospitalized for heart failure or die from heart-related causes over time. The goal is to see how effective an…